OKYO Pharma (OKYO) Insider Trading & Ownership $3.27 +0.11 (+3.48%) Closing price 08/8/2025 04:00 PM EasternExtended Trading$3.18 -0.09 (-2.60%) As of 08/8/2025 07:26 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Insider Trades Stock AnalysisAnalyst ForecastsChartCompetitorsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrendsBuy This Stock OKYO Pharma (NASDAQ:OKYO) Insider Buying and Selling ActivityCurrentInsider OwnershipPercentage40.46%Number OfInsiders Buying(Last 3 Years)1Amount OfInsider Buying(Last 3 Years)$25.01KNumber OfInsiders Selling(Last 3 Years)0 Get OKYO Insider Trade Alerts Want to know when executives and insiders are buying or selling OKYO Pharma stock? Sign up for InsiderTrades.com's daily newsletter to get the latest insider transactions delivered to your inbox daily. Email Address OKYO Insider Buying and Selling by Quarter OKYO Pharma Insider and Congressional Trades History Insiders and Members of Congress Insiders Only Members of Congress Only Transaction Type Custom Range 1 Month 3 Months 6 Months Year-to-Date 1 Year 2 Years 3 Years Time Frame Start Date End Date Export to Excel Transaction DateNameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails9/15/2023John P BrancaccioDirectorBuy16,670$1.50$25,005.00 (Data available from 1/1/2013 forward) OKYO Insider Trading Activity - Frequently Asked Questions Who is on OKYO Pharma's Insider Roster? The list of insiders at OKYO Pharma includes John P Brancaccio. Learn more on insiders at OKYO. What percentage of OKYO Pharma stock is owned by insiders? 40.46% of OKYO Pharma stock is owned by insiders. Learn more on OKYO's insider holdings. Which OKYO Pharma insiders have been buying company stock? The following insider purchased OKYO shares in the last 24 months: John P Brancaccio ($25,005.00). How much insider buying is happening at OKYO Pharma? Insiders have purchased a total of 16,670 OKYO shares in the last 24 months for a total of $25,005.00 bought. OKYO Pharma Key ExecutivesDr. Gary S. Jacob Ph.D. (Age 77)CEO & Executive Director Compensation: $650kMr. Michael Paul Beck (Age 67)Founder Ms. Keeren Shah (Age 48)Chief Financial Officer Dr. William A. Clementi Ph.D.Pharm.D., Chief Operating OfficerDr. Rajkumar Patil Ph.D. (Age 65)Chief Scientific Officer More Insider Trading Tools from MarketBeat Related Companies Upexi Insider Transactions Savara Insider Transactions aTyr Pharma Insider Transactions Flora Growth Insider Transactions COMPASS Pathways Insider Transactions Kodiak Sciences Insider Transactions Erasca Insider Transactions Tectonic Therapeutic Insider Transactions Palvella Therapeutics Insider Transactions REGENXBIO Insider Transactions Insider Tracking Tools CEO Purchases/Sales CFO Purchases/Sales Top Insider Buying Stocks Top Insider Selling Stocks Insider Trades Screener Insider Trades Newsletter Congressional Stock Trades Insider Trading By Country U.S. Insider Trading Activity Canadian Insider Trading Activity U.K. Insider Trading Activity Australia Insider Trading Activity Latest Articles Strategy Insiders Buy In While Analysts Predict Big UpsideThe Bottom Is in For These 3 Small-Cap Stocks Insiders Are Buying3 Catalysts Driving Plug Power’s Turnaround CaseInsider Selling Hits Market Leaders—Should You Be Worried?Insiders Spent Millions on These 3 Stocks Over the Past 2 Months This page (NASDAQ:OKYO) was last updated on 8/10/2025 by MarketBeat.com Staff From Our PartnersGENIUS Act: Cancel Your Money?A new law called the GENIUS Act could quietly trigger the most radical shift in American finance in decades. B...Priority Gold | SponsoredTrump’s national nightmare is herePorter Stansberry and Jeff Brown say a new U.S. national emergency is already underway — and it could trigger ...Porter & Company | SponsoredAltucher: $900 to $108,000? Trump’s “Great Gain” Is HereJames Altucher says two recent events could trigger a historic wealth shift—one driven by a radical Trump poli...Paradigm Press | Sponsored"Death Spiral" Threatening Your SavingsThe "Death Spiral" Threatening Your Savings But this time, it's not just Dalio ringing the alarm bells…Goldco Precious Metals | SponsoredTake a look at this picture ...A strange investment secret — discovered just a few short weeks before this image was taken — correctly predic...Weiss Ratings | SponsoredNational 'Stock Market Reset' Coming September 30 (New WH Order)Crash Coming Sept 30? Analysts Warn of New Crisis A new problem on the U.S. power grid is putting millions ...Altimetry | SponsoredFed Decision Warning: How to Protect Your Wealth Before September 17th On September 17th, the Fed faces an impossible choice—and Wall Street insiders are already preparing for the...American Alternative | SponsoredSell this, buy thatWhat you don’t own matters just as much as what you do. That’s the thinking behind Eric Fry’s long-time strate...InvestorPlace | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding OKYO Pharma Limited Sponsored ADR Please log in to your account or sign up in order to add this asset to your watchlist. Share OKYO Pharma With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
